Management of Crohn’s disease in poor responders to adalimumab

References

• FrøslieKFJahnsenJMoumBAVatnMHIBSEN GroupMucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohortGastroenterology2007133241242217681162
   PubMed Web of Science ®Google Scholar
• van DullemenHMvan DeventerSJHommesDWTreatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology199510911291357797011
   PubMed Web of Science ®Google Scholar
• BurnessCBKeatingGMAdalimumab: a review of its use in the treatment of patients with ulcerative colitisBio Drugs2013273247262
   Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology2006130232333316472588
   PubMed Web of Science ®Google Scholar
• PouwMFKrieckaertCLNurmohamedMTKey findings towards optimising adalimumab treatment: the concentration-effect curveAnn Rheum Dis Epub12102013
   Google Scholar
• WongDRPierikMSeinenMLThe pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn’s disease patientsJ Crohns Colitis20148212012823932783
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348760160812584368
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialAnn Intern Med20071461282983817470824
   PubMed Web of Science ®Google Scholar
• KarmirisKPaintaudGNomanMInfluence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s diseaseGastroenterology200913751628164019664627
   PubMed Web of Science ®Google Scholar
• RoblinXMarotteHRinaudoMAssociation between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesClin Gastroenterol Hepatol2014121808423891927
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut20075691232123917299059
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
   PubMed Web of Science ®Google Scholar
• ColombelJFSchwartzDASandbornWJAdalimumab for the treatment of fistulas in patients with Crohn’s diseaseGut200958794094819201775
   PubMed Web of Science ®Google Scholar
• DewintPHansenBEVerheyEAdalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI)Gut201463229229923525574
   PubMed Web of Science ®Google Scholar
• YanaiHHanauerSBAssessing response and loss of response to biological therapies in IBDAm J Gastroenterol2011106468569821427713
   PubMed Web of Science ®Google Scholar
• D’HaensGRPanaccioneRHigginsPDThe London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Am J Gastroenterol2011106219921221045814
   PubMed Web of Science ®Google Scholar
• AllezMKarmirisKLouisEReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsJ Crohns Colitis20104435536621122530
   PubMed Web of Science ®Google Scholar
• SiegelCAMelmedGYPredicting response to Anti-TNF Agents for the treatment of crohn’s diseaseTherap Adv Gastroenterol200924245251
   PubMedGoogle Scholar
• SandbornWJColombelJFEnnsRInternational Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial GroupEvaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial GroupNatalizumab induction and maintenance therapy for Crohn’s diseaseN Engl J Med2005353181912192516267322
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPGEMINI 2 Study GroupVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• HoGTSmithLAitkenSThe use of adalimumab in the management of refractory Crohn’s diseaseAliment Pharmacol Ther200827430831518081730
   PubMed Web of Science ®Google Scholar
• AllezMVermeireSMozziconacciNThe efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodiesAliment Pharmacol Ther20103119210119709098
   PubMed Web of Science ®Google Scholar
• ChaparroMAndreuMBarreiro-de AcostaMEffectiveness of infliximab after adalimumab failure in Crohn’s diseaseWorld J Gastroenterol201218375219522423066316
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRACCENT I Study GroupMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet4200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICPRECISE 2 Study InvestigatorsMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med2007357323925017634459
   PubMed Web of Science ®Google Scholar
• JonesJLoftusEVJrPanaccioneRRelationships between disease activity and serum and fecal biomarkers in patients with Crohn’s diseaseClin Gastroenterol Hepatol20086111218122418799360
   PubMed Web of Science ®Google Scholar
• HenriksenMJahnsenJLygrenIIBSEN Study GroupC-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based studyGut200857111518152318566104
   PubMed Web of Science ®Google Scholar
• KissLSSzamosiTMolnarTHungarian IBD Study GroupEarly clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s diseaseAliment Pharmacol Ther201134891192221883326
   PubMed Web of Science ®Google Scholar
• MaoRXiaoYLGaoXFecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studiesInflamm Bowel Dis201218101894189922238138
   PubMed Web of Science ®Google Scholar
• MolanderPaf BjörkestenCGMustonenHFecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agentsInflamm Bowel Dis201218112011201722223566
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWSONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• ChiuYLRubinDTVermeireSSerum adalimumab concentration and clinical remission in patients with Crohn’s diseaseInflamm Bowel Dis20131961112112223584130
   PubMed Web of Science ®Google Scholar
• AfifWLoftusEVJrFaubionWAClinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel diseaseAm J Gastroenterol201010551133113920145610
   PubMed Web of Science ®Google Scholar
• LopezABillioudVPeyrin-BirouletCPeyrin-BirouletLAdherence to anti-TNF therapy in inflammatory bowel diseases: a systematic reviewInflamm Bowel Dis20131971528153323518810
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFSchreiberSDosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomicsInflamm Bowel Dis201117114115120848500
   PubMed Web of Science ®Google Scholar
• BillioudVSandbornWJPeyrin-BirouletLLoss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic reviewAm J Gastroenterol2011106467468421407178
   PubMed Web of Science ®Google Scholar
• BaertFGlorieusEReenaersCBIRD (Belgian IBD Research and Development)Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patientsJ Crohns Colitis20137215416022537637
   PubMed Web of Science ®Google Scholar
• LouisEMaryJYVernier-MassouilleGGroupe D’etudes Thérapeutiques Des Affections Inflammatoires DigestivesMaintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stoppedGastroenterology20121421637021945953
   PubMed Web of Science ®Google Scholar
• MokCCvan der KleijDWolbinkGJDrug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseasesClin Rheumatol201332101429143523887439
   PubMed Web of Science ®Google Scholar
• WestRLZelinkovaZWolbinkGJImmunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s diseaseAliment Pharmacol Ther20082891122112618691349
   PubMed Web of Science ®Google Scholar
• de SilvaPSNguyenDDSaukJKorzenikJYajnikVAnanthakrishnanANLong-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel diseaseAliment Pharmacol Ther201236545946622784296
   PubMed Web of Science ®Google Scholar
• BrandseJFPetersCPGecseKBEffects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn’s diseaseInflamm Bowel Dis201420225125824378599
   PubMed Web of Science ®Google Scholar
• Ben-HorinSKopylovUChowersYOptimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmun Rev2014131243023792214
   PubMed Web of Science ®Google Scholar
• ChowersYSturmASansMReport of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonistsJ Crohns Colitis20104436737621122531
   PubMed Web of Science ®Google Scholar
• FinckhACiureaABrulhartLPhysicians of the Swiss Clinical Quality Management Program for Rheumatoid ArthritisB cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis Rheum20075651417142317469098
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLCERTIFI Study GroupUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• HaCUllmanTASiegelCAKornbluthAPatients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient populationClin Gastroenterol Hepatol20121091002100722343692
   PubMed Web of Science ®Google Scholar
• ReenaersCLouisEBelaicheJSeidelLKeshavSTravisSDoes co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab?Aliment Pharmacol Ther20123611–121040104823061650
   PubMed Web of Science ®Google Scholar